<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Bionexus Gene Lab Corp Common Stock — News on 6ix</title>
<link>https://6ix.com/company/bionexus-gene-lab-corp-common-stock</link>
<description>Latest news and press releases for Bionexus Gene Lab Corp Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 11 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/bionexus-gene-lab-corp-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354ca778dffbe2df0e59a2.webp</url>
<title>Bionexus Gene Lab Corp Common Stock</title>
<link>https://6ix.com/company/bionexus-gene-lab-corp-common-stock</link>
</image>
<item>
<title>BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform</title>
<link>https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-announces-appointment-of-dr-muthu-meyyappan-as-chief-commercial-officer-of-fidelion-diagnostics-to-lead-global-commercialization-of-the-vitaguardtm-mrd-platform-2</link>
<guid isPermaLink="true">https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-announces-appointment-of-dr-muthu-meyyappan-as-chief-commercial-officer-of-fidelion-diagnostics-to-lead-global-commercialization-of-the-vitaguardtm-mrd-platform-2</guid>
<pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
<description>KUALA LUMPUR, Malaysia, March 11, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC) today announced that, in connection with its Fidelion</description>
</item>
<item>
<title>BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman</title>
<link>https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-completes-chemrex-governance-restructuring-appoints-matthew-barsing-as-chairman</link>
<guid isPermaLink="true">https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-completes-chemrex-governance-restructuring-appoints-matthew-barsing-as-chairman</guid>
<pubDate>Mon, 23 Feb 2026 13:30:00 GMT</pubDate>
<description>Enhanced board oversight aligns subsidiary with disciplined capital allocation and strategic evaluation framework KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), today announced the completion of a governance restructuring of its wholly owned subsidiary, Chemrex Corporation Sdn. Bhd. (“Chemrex”). As part of this restructuring, Chemrex’s board has been streamlined to two directors: Matthew L. Barsing, ChairmanAngeline</description>
</item>
<item>
<title>BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN’s Multi-Billion Dollar Market</title>
<link>https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-launches-regional-deployment-vitaguard-140000822</link>
<guid isPermaLink="true">https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-launches-regional-deployment-vitaguard-140000822</guid>
<pubDate>Wed, 28 Jan 2026 14:00:00 GMT</pubDate>
<description>BioNexus Gene Lab Corp ($BGLC), Fidelion, and Tongshu Gene, Patent Support Signing The CEO of BioNexus Gene Lab Corp. (Nasdaq: BGLC), Sam Tan with the CEO of Tongshu Gene, Dr. Yan Linghua, together with the BGLC and Fidelion Team during the signing of a Patent Support Agreement for the development of new, upgraded Patents & Global IP. KUALA LUMPUR, Malaysia, Jan. 28, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a technology-driven precision diagn</description>
</item>
<item>
<title>BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™</title>
<link>https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-completes-134500283</link>
<guid isPermaLink="true">https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-completes-134500283</guid>
<pubDate>Wed, 03 Dec 2025 13:45:00 GMT</pubDate>
<description>KUALA LUMPUR, Malaysia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC) ("BGLC" or the "Company"), a biotechnology company advancing precision diagnostics and gene-based technologies, today announced the formal completion of its strategic transaction with Fidelion Diagnostics Pte. Ltd. ("Fidelion") and Tongshu Biotechnology. With the closing of the agreements, BGLC has become a strategic shareholder in Fidelion Diagnostics and secured exclusive commercial rights for the</description>
</item>
<item>
<title>BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization</title>
<link>https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-nasdaq-130500728</link>
<guid isPermaLink="true">https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-nasdaq-130500728</guid>
<pubDate>Tue, 02 Dec 2025 13:05:00 GMT</pubDate>
<description>SHERIDAN, Wyo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“BGLC” or the “Company”), an emerging provider of precision oncology diagnostics with expanding operations across Southeast Asia, today announced it has entered into a $500,000,000 Equity Purchase Agreement (the “Facility”) with ARC Group International Ltd. (“ARC”), a global investment bank and the parent of ARC Group Securities, a FINRA registered broker dealer. The Company believes this facility will provide it with lon</description>
</item>
<item>
<title>BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard™ MRD Platform as Part of Strategic Alliance with Tongshu Gene</title>
<link>https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-nasdaq-130000191</link>
<guid isPermaLink="true">https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-nasdaq-130000191</guid>
<pubDate>Mon, 01 Dec 2025 13:00:00 GMT</pubDate>
<description>KUALA LUMPUR, Malaysia and SINGAPORE, Dec. 01, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“BGLC”) today announced that it has executed an Exclusive Intellectual Property License Agreement for Southeast Asia with Fidelion Diagnostics Pte. Ltd. (“Fidelion”) for the VitaGuard™ minimal residual disease (“MRD”) liquid biopsy platform. The license is a key condition precedent to the closing of the previously announced Share Subscription and Shareholders’ Agreement among BGLC, Fidelion and Tongs</description>
</item>
<item>
<title>BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization</title>
<link>https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-nasdaq-130000579</link>
<guid isPermaLink="true">https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-nasdaq-130000579</guid>
<pubDate>Wed, 12 Nov 2025 13:00:00 GMT</pubDate>
<description>The signing of the definitive Share Subscription and Shareholder Agreement between BioNexus Gene Lab Corp, Fidelion Diagnostics, and Tongshu Gene (L) Sam Tan, CEO of BioNexus Gene Lab Corp. (BGLC) with (R) Dr. Yan Linghua, CEO of Tongshu Gene signing the Share Subscription and Shareholder Agreement between BioNexus Gene Lab Corp, Fidelion Diagnostics, and Tongshu Gene KUALA LUMPUR, Malaysia and SINGAPORE, Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“BGLC,” Nasdaq: BGLC) today anno</description>
</item>
<item>
<title>BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities</title>
<link>https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-files-130000543</link>
<guid isPermaLink="true">https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-files-130000543</guid>
<pubDate>Mon, 10 Nov 2025 13:00:00 GMT</pubDate>
<description>KUALA LUMPUR, Malaysia, Nov. 10, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a biotechnology company advancing precision diagnostics and gene-based technologies across Asia and the U.S., today announced that it has filed a registration statement on Form S-3 with the U.S. Securities and Exchange Commission (“SEC”) to register up to $100 million of securities that may be offered from time to time.Under this shelf, the Company has entered into an E</description>
</item>
<item>
<title>BioNexus Gene Lab Corp Signs Strategic Partnership Term Sheet with BirchBioMed Inc.</title>
<link>https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-signs-strategic-partnership-term-sheet-with-birchbiomed-inc</link>
<guid isPermaLink="true">https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-signs-strategic-partnership-term-sheet-with-birchbiomed-inc</guid>
<pubDate>Mon, 20 Oct 2025 04:00:00 GMT</pubDate>
<description>Collaboration Expected to Advance FS2 Topical Platform and Strengthen BGLC’s Biotech Footprint in Asia KUALA LUMPUR, Malaysia, Oct. 20, 2025 (GLOBE NEWSWIRE)</description>
</item>
<item>
<title>BioNexus Gene Lab Corp. and Fidelion Diagnostics Announce Landmark Alliance—Touted as a new “DeepSeek Moment” in Precision Oncology</title>
<link>https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-fidelion-120000762</link>
<guid isPermaLink="true">https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-fidelion-120000762</guid>
<pubDate>Wed, 30 Jul 2025 12:00:00 GMT</pubDate>
<description>KUALA LUMPUR, Malaysia, July 30, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“BGLC”, Nasdaq: BGLC) and Fidelion Diagnostics Pte Ltd, a Singaporean company (“Fidelion”) today announced the signing of a term sheet for a strategic, cross-equity partnership that the parties are calling a “DeepSeek-class leap” for liquid biopsy cancer monitoring and AI-driven biotechnology. This builds on BGLC’s mission to be a global leader in liquid biopsies, and tumor naïve oncology solutions. Under the term</description>
</item>
<item>
<title>BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness</title>
<link>https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-regains-152500158</link>
<guid isPermaLink="true">https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-regains-152500158</guid>
<pubDate>Wed, 30 Apr 2025 15:25:00 GMT</pubDate>
<description>KUALA LUMPUR, Malaysia, April 30, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC), a biotechnology company specializing in precision diagnostics and specialty chemical solutions, today announced that it has received official notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming the Company has regained full compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. This important milestone reaffirms the Company’s standing</description>
</item>
<item>
<title>BioNexus Gene Lab Corp. Files 2024 Annual Report Highlighting Strategic Innovation, Operational Resilience, and Growth Trajectory</title>
<link>https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-files-150000216</link>
<guid isPermaLink="true">https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-files-150000216</guid>
<pubDate>Tue, 15 Apr 2025 15:00:00 GMT</pubDate>
<description>KUALA LUMPUR, Malaysia, April 15, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a diversified biotechnology and specialty materials group headquartered in Malaysia and incorporated in Wyoming, today announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission. The Company’s 2024 report showcases a year of strategic realignment, technological advancement, and en</description>
</item>
<item>
<title>BioNexus Gene Lab Corp. Announces Board Approval of Ethereum Treasury Strategy and Release of Strategic Whitepaper</title>
<link>https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-announces-board-approval-of-ethereum-treasury-strategy-and-release-of-strategic-whitepaper</link>
<guid isPermaLink="true">https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-announces-board-approval-of-ethereum-treasury-strategy-and-release-of-strategic-whitepaper</guid>
<pubDate>Wed, 05 Mar 2025 05:00:00 GMT</pubDate>
<description>KUALA LUMPUR, Malaysia, March 06, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC), a technology company dedicated to innovation in technology</description>
</item>
<item>
<title>BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd.</title>
<link>https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corporation-announces-entry-into-biogas-sector-via-teaming-agreement-with-protech-builders-sdn-bhd</link>
<guid isPermaLink="true">https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corporation-announces-entry-into-biogas-sector-via-teaming-agreement-with-protech-builders-sdn-bhd</guid>
<pubDate>Wed, 25 Sep 2024 04:00:00 GMT</pubDate>
<description>KUALA LUMPUR, Malaysia, Sept. 25, 2024 (GLOBE NEWSWIRE) -- MRNA Scientific Sdn. Bhd. ("MRNA"), a subsidiary of BioNexus Gene Lab Corp. (Nasdaq: BGLC, the</description>
</item>
<item>
<title>BioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd.</title>
<link>https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-signs-strategic-outsourcing-agreement-with-vitarray-global-pte-ltd</link>
<guid isPermaLink="true">https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-signs-strategic-outsourcing-agreement-with-vitarray-global-pte-ltd</guid>
<pubDate>Fri, 13 Sep 2024 04:00:00 GMT</pubDate>
<description>KUALA LUMPUR, Malaysia, Sept. 14, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC, the “Company”), an emerging biotechnology company focused on</description>
</item>
<item>
<title>BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions</title>
<link>https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-signs-strategic-partnership-mou-with-shenzhen-rongguang-group-to-advance-cancer-screening-precision-medicine-and-preventative-healthcare-solutions</link>
<guid isPermaLink="true">https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-signs-strategic-partnership-mou-with-shenzhen-rongguang-group-to-advance-cancer-screening-precision-medicine-and-preventative-healthcare-solutions</guid>
<pubDate>Thu, 12 Sep 2024 04:00:00 GMT</pubDate>
<description>KUALA LUMPUR, Malaysia, Sept. 13, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC, the “Company”), an emerging biotechnology company focused on</description>
</item>
<item>
<title>BioNexus Gene Lab Corp Announces New Business Developments for Subsidiary Chemrex with Investment in High-Quality Color Paste Production</title>
<link>https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-announces-new-business-developments-for-subsidiary-chemrex-with-investment-in-high-quality-color-paste-production</link>
<guid isPermaLink="true">https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-announces-new-business-developments-for-subsidiary-chemrex-with-investment-in-high-quality-color-paste-production</guid>
<pubDate>Wed, 11 Sep 2024 04:00:00 GMT</pubDate>
<description>KUALA LUMPUR, Malaysia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp (Nasdaq: BGLC, the “Company”), an emerging Biotech & Chemicals company, is</description>
</item>
<item>
<title>BioNexus Gene Lab Corp. Announces Successful Securities Commission of Malaysia (MyCIF) Co-Investment in Ascension Innovation Sdn Bhd</title>
<link>https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-announces-successful-securities-commission-of-malaysia-mycif-co-investment-in-ascension-innovation-sdn-bhd</link>
<guid isPermaLink="true">https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-announces-successful-securities-commission-of-malaysia-mycif-co-investment-in-ascension-innovation-sdn-bhd</guid>
<pubDate>Tue, 27 Aug 2024 04:00:00 GMT</pubDate>
<description>KUALA LUMPUR, Malaysia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC), an emerging leader in genomic diagnostics and personalized</description>
</item>
<item>
<title>BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd</title>
<link>https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-completes-strategic-rm-1-million-investment-in-ascension-innovation-sdn-bhd</link>
<guid isPermaLink="true">https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-completes-strategic-rm-1-million-investment-in-ascension-innovation-sdn-bhd</guid>
<pubDate>Mon, 26 Aug 2024 04:00:00 GMT</pubDate>
<description>KUALA LUMPUR, Malaysia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC), an emerging leader in genomic diagnostics and health</description>
</item>
<item>
<title>BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare</title>
<link>https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-agrees-to-invest-rm-12-million-in-ascension-innovation-aisb-to-advance-digital-health-innovation-through-ai-adoption-in-healthcare</link>
<guid isPermaLink="true">https://6ix.com/company/bionexus-gene-lab-corp-common-stock/news/bionexus-gene-lab-corp-agrees-to-invest-rm-12-million-in-ascension-innovation-aisb-to-advance-digital-health-innovation-through-ai-adoption-in-healthcare</guid>
<pubDate>Thu, 18 Apr 2024 04:00:00 GMT</pubDate>
<description>KUALA LUMPUR, Malaysia, April 19, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corporation (NASDAQ: BGLC), a global leader in genomic diagnostics and healthcare</description>
</item>
</channel>
</rss>